Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

Fineline Cube Aug 26, 2026
Company Drug PIC

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

Fineline Cube Aug 26, 2026
Company PIC

WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs

Fineline Cube Aug 26, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Fineline Cube Aug 26, 2026
Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Fineline Cube Aug 26, 2026
Company Drug

MicroPort NeuroTech’s NUMEN Silk Receives FDA Approval for Embolization Treatment

Fineline Cube Oct 21, 2024

MicroPort NeuroTech Limited (HKG: 2172), a Chinese medical device company, has announced that it has...

Company Drug

Astellas Pharma’s Vyloy Receives FDA Approval for CLDN18.2 Positive Gastric Cancer Treatment

Fineline Cube Oct 20, 2024

Astellas Pharma (TYO: 4503) has announced that the U.S. Food and Drug Administration (FDA) has...

Company Drug

Westgene Biopharma’s Pioneering mRNA Vaccine for EBV-Related Tumors Clears IND Hurdle in China

Fineline Cube Oct 20, 2024

Westgene Biopharma has received approval from the Center for Drug Evaluation (CDE) under the National...

Company Drug

Kanghong Pharmaceutical’s NASH Drug KH629 Receives Clinical Trial Implicit Approval in China

Fineline Cube Oct 19, 2024

On October 18th, the official website of the Center for Drug Evaluation (CDE) of the...

Company

Beijing Biostar Pharmaceuticals Set to Go Public on HKEX with Focus on Oncology Innovation

Fineline Cube Oct 19, 2024

On October 18, 2024, the Hong Kong Stock Exchange announced that Beijing Biostar Pharmaceuticals Co.,...

Company Drug

Akeso Biopharma Launches Phase Ib/II Trial for Cadonilimab and AK112 in Pancreatic Cancer

Fineline Cube Oct 19, 2024

On October 17, ClinicalTrials.gov reported that Akeso Biopharma (HKG: 9926) has initiated a Phase Ib/II...

Company Drug

FDA Extends Review of Amgen’s Lumakras for KRAS G12C mCRC Treatment to January 2025

Fineline Cube Oct 19, 2024

On October 18, FirstWord reported that the U.S. FDA has extended the review period for...

Company Drug

Shenzhen Chipscreen Advances CS231295 for Cancer Treatment as IND Accepted by NMPA

Fineline Cube Oct 19, 2024

On October 17, Shenzhen Chipscreen Biosciences Co., Ltd. (SHA: 688321) announced that its innovative Class...

Company Deals

Pfizer Partners with TRIANA Biomedicines to Develop Molecular Glue Degraders for Oncology and Other Diseases

Fineline Cube Oct 18, 2024

Pfizer (NSE: PFIZER), a leading US pharmaceutical company, has entered into a strategic partnership and...

Company Drug

AstraZeneca Files for Market Approval of Tremelimumab in China for Hepatocellular Carcinoma

Fineline Cube Oct 18, 2024

The Center for Drug Evaluation (CDE) has indicated on its website that AstraZeneca (NASDAQ: AZN),...

Company Medical Device

MicroPort CardioFlow’s Heart Valve Balloon Dilatation Catheter Alwide Plus Gains Mexican Approval

Fineline Cube Oct 18, 2024

MicroPort Scientific Corp., a leading Chinese medical device company (HKG: 0853), through its spin-off MicroPort...

Company Drug

Changshan Biochemical Pharmaceutical Wins Marketing Approval for Enoxaparin in Niger

Fineline Cube Oct 18, 2024

Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255), a Chinese pharmaceutical company, has announced...

Company Drug

Huahai Pharmaceutical Gets FDA Nod for Generic Empagliflozin and Metformin ANDA

Fineline Cube Oct 18, 2024

Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521), a prominent Chinese pharmaceutical company, has announced the...

Company Drug

Laekna Advances Obesity Treatment Candidate LAE102 with Subcutaneous Dosing in Phase I Study

Fineline Cube Oct 18, 2024

Laekna, a Sino-US biotech firm, has announced the commencement of a subcutaneous dosing cohort within...

Company Deals

Sanofi Invests EUR 300 Million in Joint Venture with Orano Med for Next-Generation Radioligand Therapies

Fineline Cube Oct 18, 2024

Sanofi (EPA: SAN), a leading French pharmaceutical company, has entered into a strategic agreement with...

Company Drug

Antengene’s Xpovio Secures Expanded Access in South Korea for Multiple Myeloma Treatment

Fineline Cube Oct 18, 2024

Antengene Corp., Ltd (HKG: 6996), a China-based biopharmaceutical company, has announced that it has received...

Company Drug

AbbVie’s Vyalev Wins FDA Approval as First Subcutaneous Levodopa Therapy for Advanced Parkinson’s

Fineline Cube Oct 18, 2024

AbbVie (NYSE: ABBV), a leading pharmaceutical company based in the US, has received approval from...

Policy / Regulatory

Chengdu Drafts Comprehensive Policy to Stimulate Biomedical Industry Growth

Fineline Cube Oct 18, 2024

The Chengdu Municipal Bureau of Economic and Information Technology has unveiled a draft proposal titled...

Company Drug

Chongqing Zhifei Biological’s EC Injection Receives Market Approval in Indonesia

Fineline Cube Oct 18, 2024

Chongqing Zhifei Biological Co., Ltd (SHE: 300122), a leading biopharmaceutical company based in China, has...

Company Deals

Tencent Invests USD 30 Million in Early Cancer Detection Firm Insighta, Backed by Prenetics

Fineline Cube Oct 18, 2024

Prenetics Global Limited (NASDAQ: PRE), a prominent health sciences company with operations in the US...

Posts pagination

1 … 328 329 330 … 712

Recent updates

  • NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer
  • FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab
  • FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma
  • MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan
  • WuXi Biologics 2026H1 Revenue Climbs 18.4% to RMB 11.8 Billion as Project Pipeline Hits 1,064 Integrated Programs
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug PIC

NMPA Approves Novartis’ Pluvicto Plus ARPI for PSMA‑Positive mHSPC in China, Advancing Radioligand Therapy to Earlier Prostate Cancer

Company Drug PIC

FDA Approves J&J’s IMAAVY for Warm Autoimmune Hemolytic Anemia, Marking Second Indication for Nipocalimab

Company Drug PIC

FDA Approves BeOne’s Tevimbra Plus Zanidatamab and Chemotherapy for First‑Line HER2‑Positive Gastroesophageal Adenocarcinoma

Company Drug PIC

MHLW Approves Takeda’s First‑in‑Class ORZEYFUL (Oveporexton) for Narcolepsy Type 1 in Japan

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2026 | Fineline Information & Technology | BlogData by Themeansar.